Post by Stefan König

I am excited to share that Merz Therapeutics has officially closed on the acquisition of two therapies, INBRIJA® and AMPYRA®, from Acorda Therapeutics, allowing us to expand our treatments for people with Parkinson’s disease and walking difficulties from multiple sclerosis (MS).    At Merz Therapeutics, we take great pride in exploring new growth opportunities and advancing our knowledge of the movement disorder space. I am proud to be a part of an organization that continues to put patient's needs first and am thrilled to be part of this pivotal journey.      Since assuming the role of CEO, it has been a goal of mine to broaden our product portfolio and offer more treatment options for individuals impacted by #MovementDisorders. With this acquisition, it brings us one step closer to becoming a leading player in neurology-focused pharma. I look forward to seeing Merz Therapeutics actively step into the MS segment and hope to have further opportunities to explore other therapeutic areas.    Thanks to all who have played a vital role in making this acquisition a success. Together, we are moving forward with a shared vision of creating #BetterOutcomesForMorePatients.    Read more here: https://lnkd.in/d-hMZVtf